The U.S. Food and Drug Administration (FDA) has awarded a $5.6 million contract to Harvard University’s Wyss Institute for Biologically Inspired Engineering to apply its breakthrough organs-on-chips technology to assess medical countermeasures for treating acute radiation syndrome (ARS), also known as radiation sickness.
Patients with diarrhea-predominant irritable bowel syndrome, or IBS-D, treated with eluxadoline achieved better clinical response and experienced more symptom improvement than those using placebo, according to a recent study. Eluxadoline, which is currently in phase 3 trials, is under development as a potential treatment for IBS-D.
Cedars-Sinai Medical Center has launched a phase 1 clinical trial to study the safety and tolerability of an experimental immunization to treat Alzheimer’s disease. The treatment is based on Copaxone (glatiramer acetate), a drug often prescribed to reduce the frequency of multiple sclerosis relapses.
A new strategy that cripples the ability of the dengue virus to escape the host immune system has been discovered by A*STAR's Singapore Immunology Network (SIgN). This breakthrough strategy opens a door of hope to what may become the world's first universal dengue vaccine candidate that can give full protection from all four serotypes of the dreadful virus.
A Human Papillomavirus (HPV) vaccine significantly protects women against oral HPV infection, not just cervical HPV infection, suggests a new PLOS One study. If the study results are substantiated, experts say the vaccine may also have a significant impact on the prevalence of throat cancer, an HPV-linked cancer with rates that have climbed steadily in the last 30 years.
Teva Pharmaceutical Industries Ltd. and Perrigo Company announced the launch of the generic equivalent to Temodar (temozolomide). Teva will manufacture, market and distribute the product in the U.S. and both companies will equally share in the cost and profitability of the product in the U.S.
Vical Incorporated announced top-line results from a phase 3 trial of Allovectin (velimogene aliplasmid) in patients with metastatic melanoma. The 390-subject trial failed to demonstrate a statistically significant improvement versus first-line chemotherapy for either the primary endpoint of objective response rate at 24 weeks or more after randomization or the secondary endpoint of overall survival.
Janssen-Cilag International NV (Janssen) announced that the European Commission (EC) has approved the use of Velcade (bortezomib) as induction therapy (a first therapeutic option) in combination with dexamethasone or thalidomide and dexamethasone.
An international scientific collaborative has discovered why women who give birth in their early 20s are less likely to develop breast cancer eventually than women who don’t. If the hypothesis is confirmed, the commercial development of a clinical test for breast cancer risk would follow.
Cancer Research UK-funded scientists have discovered that experimental drugs first developed for breast and ovarian cancer could be used to treat the most common type of lung cancer, recent research reveals. The study showed how experimental drugs called PARP inhibitors could be useful in up to half of non-small-cell lung cancer.
In 1958 a group of scientists working in Denmark observed that bacterial cells are about twice as large when they are cultured on a rich nutrient source than when they are cultured on a meager one. It has taken 60 years to figure out how the bacteria are able to sample their surroundings and alter their cell cycles so that they grow to a size suited to the environment.
Medtronic Inc. announced the closing of the acquisition of Cardiocom, a privately held developer and provider of integrated telehealth and patient services for the management of chronic diseases, in an all cash transaction valued at $200 million. Medtronic expects the net impact from this transaction to be neutral to fiscal year 2014 earnings.
West Virginia Attorney General Patrick Morrisey has recused himself from two lawsuits filed by the office against drug companies. Morrisey's wife, Denise Henry, lobbies for two of the companies, Sanofi and Cardinal Health, and Morrisey is a former lobbyist for Sanofi, the Sunday Gazette-Mail reported.
The U.S. Food and Drug Administration (FDA) is alerting health care providers and patients of a voluntary nationwide recall of all products produced and distributed for sterile use by Specialty Compounding, LLC, Cedar Park, TX. There have been recent reports of bacterial bloodstream infections potentially related to the company's calcium gluconate infusions.
Chinese authorities have launched an investigation against French drugmaker Sanofi following a news report that accused the company of bribing hundreds of Chinese doctors in 2007. An unnamed whistleblower told the Guangzhou-based, state-owned 21st Century Business Herald that the French company had paid 503 doctors a total of $274,000 to prescribe Sanofi products, disguising the payments as grants for research programs.